Gsk Share Discussion Threads

[tompion] 28/4/2015 12:25

I think the xd date has not yet been fixed and current buyers will get the special payment - not a great fan of these schemes myself.

[tradermichael] 28/4/2015 11:29

treble: Its associated with the deal with Novartis:

Capital return
GSK plans to use net after tax cash proceeds of $7.8 billion to fund a capital return of £4 billion to shareholders following completion of the transaction. This return is expected to be implemented through a B share scheme in 2015, subject to approvals. Specific details related to the execution of the B share scheme will be sent to shareholders in due course.

[cyberian] 28/4/2015 11:17

TM..saw that the other day...limited application but sets a potential train of additional benefits across other genetic situations. Really pleased on the release today of the up-date on the shingles success level over an extended period..97.2% is excellent and I had mine about 2 years ago with no side effects/issues. This was a precautionary measure but in this area the application will be significant..the trial was extensive with many participants on a fairly global basis. So 1 in 3 may develop shingles over 50 years so with other vaccines in the pipe-line prospects continue to appear favourable for GSK.

[treble in 1999] 28/4/2015 11:08

I am thinking of buying here based on the divi policy.
I read something earlier about a special 83p divi, but cannot find any further information.
Can anyone enlighten me or have I misread something?

[cyberian] 27/4/2015 22:02

Bloomberg reporting today that in the US there was a bullish sign detected early on with 22 times the normal level of June 49 calls (believe 4,000 contracts), and a double of normal call volume on the May 46 issue. So a slightly more positive sign of money entering GSK on the bullish side. Traders looking at the moving 200 day levels and looking forward to the 1Q results on May 6th. The US trading in GSK adr's was quite variable but was firm with after our trades seeing higher prices, but well below the high of the day. Time to relax, maybe!!

[cyberian] 27/4/2015 17:06

Agree Dr. I suppose with the consequence of the UK election, and the extreme uncertainties as to the form/type of Government we will have, a hostile bid may catch the political set-up off guard. Attention would be focused on striking a political strategy to move forward, unless the Conservatives somehow secure a workable majority. Even under that scenario there would be loads of domestic issues to calm, plus the furore over the 2017 EU vote to come. Oh well I do agree with TM that the fundamentals with GSK are a little understated on the positive side and the divi will be protected, and just maybe a date for the 83p B share matter will be advised on Wednesday week. That should keep everyone on their toes and perhaps re-balance the share price after the fall from 1644p last Monday?

[dr biotech] 27/4/2015 16:36

Fair play to him - if an individual of moderate wealth can really cause the DJ to plunge 1000pts then in my eyes its not him thats the problem but the way the market is set up.

I agree with Zaxx - second article is just a copy of the first. They have probably changed just enough to prevent it being a breach of copyright. Though given the credibility of the article I doubt anyone would want to try and lay claim to it.

I used to read the telegraph but its become a shadow of the paper it once was - most of the stories seem to come from the Daily Mail and the increasingly overtly right wing stance has just put me off it. They have a bit about Labours housing policy causing housebuilders to slump this morning (a couple of the housebuilder were down about 1%). Then its changed to "200m wiped off housebuiders valuations" to make it sound more dramatic. Just makes them lose credibility. I'd rather the media was neutral and lets us make our own minds up.

[tradermichael] 27/4/2015 14:46

GSK unbelievably undervalued, una!

[zzaxx99] 27/4/2015 14:15

That would be more impressive if the second article wasn't just a shameless "re-interpretation" of the first one.

[unastubbs] 27/4/2015 13:18

agree with you both, but it doesn't do any harm. hadn't realised that gsk was quite so far behind in terms of market cap as compared to pfizer, roche and novartis - if the article is correct on that point

[dr biotech] 27/4/2015 09:43

Haven't the US clamped down on tax inversions? Sounds like the editor asked for an article at short notice and said write any old rubbish.

[madengland] 27/4/2015 09:32

Excuse the grammar! An illiterate ramper is what I would be called :-)

[madengland] 27/4/2015 09:06

Nothing's impossible but a wildly speculative article. If one of us write that on a bb we would be labelled ramping.

[unastubbs] 27/4/2015 07:35

bid possible?

[madengland] 23/4/2015 12:47

It was classic kitchen sink stuff at Tesco yesterday I thought. It's on my radar, would like to have time to digest turnaround plans and likely see market disappointment that they won't turn things around as quickly as people want.... It's interesting with all the rhetoric on ZHC and minimum wage, with the supermarket sector employing probably 300-400k people and more than just Tesco struggling, if labour get in they make get a back lash if they start pushing. Anyway enough that. GSK I got out to cement capital gains and it was well timed. Added a few in Sipp but luckily procrastinated. Wonder if we will get a GSK gyration pattern like the past. GLA

[tradermichael] 23/4/2015 12:43

The pharmaceutical giant, Novartis reported a 7% drop in sales to $11.94 billion in the quarter ended March 31 from $12.77 billion a year earlier based on operations the company still owns. Analysts surveyed by Dow Jones had forecast sales of $12.61 billion.

Novartis said it expected net sales to grow in the mid-single digits for the full year, with core operating income rising at a faster high-single-digit pace.

The figures come shortly after Novartis completed a series of transactions valued at roughly $25 billion that refocused the drug group on three core areas: pharmaceuticals, generics and eye care. The sweeping overhaul, which included the purchase of GlaxoSmithKline PLC's oncology unit, has transformed Novartis into a cancer powerhouse with roughly a fifth of its revenue expected to come from cancer drugs.

Novartis also formed a joint venture with GSK to create an over-the-counter business and sold the U.K. company most of its vaccines business. Novartis also sold Eli Lilly and Co. an animal health business.

When the proceeds from those transactions are included Novartis reported a huge rise in net profit attributable to shareholders of $13 billion in the quarter ended March 31. Novartis reported $2.94 billion in net profit a year earlier.

[tradermichael] 23/4/2015 12:17

.... which makes TSCO a strange performing share?

[woodhawk] 23/4/2015 11:53

I don't think this fall is anything to do with GSK per se, other big caps are steeply off recent highs by similar percentages. Probably pre-election jitters, or just pure profit taking. As doom mongers seem to be out in force, will probably prove in retrospect to be another excellent buying opportunity.

[cyberian] 23/4/2015 10:46

Agree TM...looking at things in a more gloomy way one could say that with the 83p and the normal annual divi (which the company is commited to) one could say we are below JP Morgan's target at 1372p! Maybe a bit of and odd way at looking at events....1535p less 163p b share and annual divi.

[tradermichael] 23/4/2015 10:26

Also, just think of percentages. Its often the case with a high 'priced' share (e.g. 1600p rather than 160p) that week to week movements can appear to be daunting (i.e. 1600p dropping to 1500p seems a disaster), but there are many shares that swing between 160p and 150p, (losing 1 or 2p a day for a week and back again) and such movements are often hardly noticed.

[tradermichael] 23/4/2015 10:13

Maybe - but don't forget the dividend about 14 May, and then the 'big' one (83p) at the early part of the second half of the year. I'm happy to buy and hold for now (irrespective of the swings) - the annual 80p dividend soon mounts up.

[madengland] 23/4/2015 09:58

Looks like the bull run in GSK is over for now folks. Nice while it lasted and a nice divi in there during it. Could be a good buy again soon nearing May.